Logo

Health

As a total healthcare enterprise, the Otsuka group of companies creates innovative products and seeks ways to maintain and promote better health for all.

Addressing Unmet Needs

The Otsuka group is passionate about its philosophy to contribute to better health for people worldwide, and it does by striving to create groundbreaking new products of a kind that only Otsuka can conceive.

Addressing Unmet Medical Needs

Theme thumb otsuka pic11 1

Otsuka Pharmaceutical

Theme thumb otsuka pic11 2

Taiho Pharmaceutical

Otsuka group medical-related businesses develop revolutionary new medications in fields where unmet medical needs exist and deliver them worldwide.
One focus area for Otsuka is diseases of the central nervous system (CNS), including schizophrenia, depression, bipolar disorder, and Alzheimer’s disease. The underlying causes of these diseases have yet to be precisely elucidated, making research and development of treatments extremely challenging. Cures remain elusive, while expectations from patients and their families for new, better drugs remain high.
Otsuka Pharmaceutical began research into central nervous system diseases in the 1970s, which ultimately led to the US launch of ABILIFY, an antipsychotic and the first-ever dopamine partial antagonist, in 2002. The drug has been used to benefit the lives of patients in approximately 60 countries and regions worldwide.
CNS diseases and their treatments are often accompanied by adherence issues: patients may lack an understanding of their condition, dislike the side effects of their medication and stop taking it, or forget to take it. This often leads to disease relapses. For better patient outcomes and improved adherence, in 2013 Otsuka launched ABILIFY MAINTENA, a prolonged-release version of ABILIFY administered as a once-monthly, intramuscular injection. Additionally, as a new treatment option, the company first launched REXULTI, an antipsychotic with a new mechanism of action in the US in 2015. REXULTI was subsequently in other markets, including in Japan in April 2018.
In 2015 Otsuka Pharmaceutical acquired Avanir Pharmaceuticals, which developed NUEDEXTA, the first-ever treatment approved specifically for pseudobulbar affect (PBA*). Acquiring Avanir Pharmaceuticals has enabled Otsuka to expand its therapeutic reach in the neurologic area and complement its extensive capabilities in psychiatric diseases.
In the area of oncology, Otsuka Pharmaceutical is focusing on blood cancers, developing and commercializing ICLUSIG to treat patients with chronic myeloid leukemia. Additionally, in the cardio-renal disease areas, the company developed Samsca, the first-ever treatment to slow the progression of autosomal dominant polycystic kidney disease (ADPKD), an orphan kidney disease. (Samsca is marketed outside Japan for ADPKD under the brand names JINARC/JYNARQUE.)
In infectious diseases, one of Otsuka’s focus areas is tuberculosis, a critical public health issue worldwide. The company introduced the anti-tuberculosis drug DELTYBA in Europe and Japan in 2014. DELTYBA was included in the Model List of Essential Medicines published by the World Health Organization in 2015, and patients in more than 80 countries have accessed the drug.in more than 80 countries. Through Visterra, a US-based subsidiary acquired in 2018, Otsuka is pursuing research and development on infectious diseases such as influenza.

Taiho Pharmaceutical is one of Japan’s foremost creators of anticancer agents, with over 50 years of experience in chemotherapies. Taiho Pharmaceutical pioneered oral anticancer formulations before they became more widely available worldwide. In 1974, the company introduced the oral anticancer agent Futraful, and has since brought to market UFT (in 1984), TS-1 (in 1999), and LONSURF (in 2014).
The company strives to meet patients’ needs, including new formulations (UFT in capsules and enteric granules; and TS-1 in capsules, granules, and orally disintegrating tablets) and development of UZEL (in 2003) with the aim of strengthening the efficacy of UFT in treating colorectal cancer. These oral formulations are recommended in medical guidelines for a number of different cancers. In particular, LONSURF, a treatment approved for refractory metastatic colorectal cancer deployed as a global product, is recommended under treatment guidelines in Europe and North America. While there has been enormous recent progress in cancer treatments, significant unmet medical needs remain. Following its development in Japan, in 2015 Taiho Pharmaceutical launched Yondelis, a treatment for soft tissue sarcoma that is recommended in European and North American medical guidelines. The company also is committed to developing treatments for rare cancers in cases where unmet medical needs are deep. This company is assessing unmet medical needs from clinical practice, and is aiming for more rapid discovery and development of oncology drugs. With the patient perspectives in mind, the Otsuka group is committed to research and development on new anticancer drugs that will be integral in future cancer treatments and others that will help with supportive care, such as antiemetic agents and drugs to alleviate cancer pain.

Otsuka Pharmaceutical Factory undertakes research and development with a global frame of reference, prioritizing clinical nutrition, surgical products, and regenerative medicine with the aim of creating new value. In the area of clinical nutrition, the company used its pioneering IV container technology to develop an antibiotics kit that enables antibiotics and solvents to be prepared in a sterile environment with a single press, as well as ELNEOPA Injection No. 1 and No. 2, high-calorie, total parenteral nutrition solutions containing glucose, electrolytes, amino acids, multiple vitamins, and trace elements in the first-ever, quad-chamber bag. These revolutionary new products help improve convenience and prevent medical errors.
In 2017, Otsuka Pharmaceutical Factory launched ELNEOPA NF Injection No. 1 and No. 2, new formulas developed on the basis of prescriptions written outside Japan where ELNEOPA is widely used. In addition to working on improvements of existing products, the company also focuses on research into next-generation clinical nutrition products with treatment applications.
Otsuka Pharmaceutical Factory is also engaged in the development of surgical products. In 2015 Olanedine became the first new topical antiseptic solution to be approved in Japan in over 50 years, and the company has accelerated research expected to lead to the development of next-generation products to help prevent infectious diseases and post-surgery complications. Otsuka Pharmaceutical Factory engages in regenerative medicine research in both the US and Japan. The company focuses on bioartificial pancreas islets, an area that shows promise as a more effective method of type 1 diabetes treatment, as well as research intended to help create highly functional products that will enable a wide range of hospitals and clinics to provide cellular treatment. In addition to these priority areas, Otsuka Pharmaceutical Factory has also established project teams for the purpose of creating revolutionary new drugs.
In order to create the products that patients truly need, the company is committed to listening to patients and healthcare professionals from the earliest stages to identify issues that could emerge in the future, and consequently develop a flexible approach that is not confined to existing frameworks.

* Pseudobulbar affect (PBA) is a neurological disorder in which individuals cannot control their feelings or actions. It is characterized by involuntary outbursts of crying in front of others and laughing in inappropriate situations.
 
Otsuka Pharmaceutical, Otsuka Pharmaceutical Factory, Taiho Pharmaceutical

Addressing Yet-to-be-imagined Consumer Needs

Theme thumb  img 7755 %e5%b7%ae%e3%81%97%e6%9b%bf%e3%81%88170707

Otsuka Pharmaceutical: Saga Nutraceuticals Research Institute

Theme thumb img labo02

Otsuka Pharmaceutical: Otsu Nutraceuticals Research Institute

In our nutraceutical business, Otsuka Pharmaceutical leverages our medical-related expertise to develop original functional foods, beverages and other scientifically-based products to maintain and promote the health of people around the world. The company’s perseverance in communicating the value of these functional products has created new markets. Today, Japan and many other developed countries face a number of social issues, including aging populations, declining birthrates and increasing burdens from medical expenses, which has lead the company to focus on yet-to-be-imagined needs in extending healthy life expectancies, and in women’s health.
In 1980, the company launched POCARI SWEAT, a health drink that replenishes water and electrolytes lost to sweat. Since the product’s launch nearly 40 years ago, the Otsuka Pharmaceutical Saga Nutraceuticals Research Institute has conducted research on electrolyte and fluid replacement. Simultaneously, the company has conveyed the importance of hydration, including electrolytes, and provides support in a variety of situations. Educational events at sports venues have helped ensure that proper hydration is an essential component of athletes’ training regimens.
In 2016, the company launched POCARI SWEAT JELLY, an edible form of hydration, to appeal to those who fail to hydrate despite understanding the need to do so. In 2017, the company launched BODYMAINTÉ JELLY. This product addresses the paradox that even top athletes, who pay extremely careful attention to their physical condition, can lose their peak condition during important competitions. The company believes that investigating the rigorous daily training conditions in which athletes can build peak condition for the “big game”, has implications for the maintenance of the physical condition of all people, therefore we have combined our research results regarding “exercise and nutrition” and “intestines and nutrition”. The product is formulated with lactic acid bacteria B240* as well as the ingredient necessary for physical conditioning. Our involvement in the maintenance and improvement of health extends beyond athletes who are at risk of losing their peak condition to all consumers concerned about maintaining their day-to-day health.
Moreover, in 2016, Otsuka Pharmaceutical joined with the Japan Sport Council (JSC) High Performance Center to launch the Total Conditioning Research Project, a collaborative research project between industry, government and academia to advance sports medicine and science to boost Japan’s international sports competitiveness. The knowledge gained from this research will be used to develop guidelines for sports conditioning that will serve as a soft legacy beyond 2020, informing educational activities for the maintenance and improvement of the health of the general population.
With regard to women’s health, Otsuka Pharmaceutical has explored the possibilities of soybeans for decades, focusing on the isoflavones contained in soybeans. Moreover, the company discovered in its research that equol, an ingredient derived through intestinal bacteria from one kind of soybean isoflavones, is closely tied to women’s health. In 2014, the company launched EQUELLE, which contains equol to help women stay healthy and beautiful during and after the midlife transitional period when they experience various physical and nonphysical changes. In 2018 the company launched the jelly-type beverage EQUELLE Gelée which combines in one pouch ingredients that women want to ingest, such as equol, collagen, calcium and other ingredients. This means that it has become possible to ingest equol even more easily. EQUELLE Gelée new concept goes beyond surface solutions, offering fundamental support for women's beauty and health from the inside out. Furthermore, in 2017 Otsuka’s Saga Nutraceuticals Research Institute and Kindai University (both in Japan) released the results of joint research in pursuit of the further health benefits of equol. The company will continue researching solutions for women’s health issues and ways to improve women’s quality of life.

* Lactic acid B240 was isolated by Tokyo University of Agriculture and confirmed for efficacy by Otsuka Pharmaceutical.
Otsuka Pharmaceutical

Global Initiatives for Public Health

Theme thumb img fightback

To raise awareness of the dangers and treatability of pulmonary tuberculosis, Otsuka Pharmaceutical worked with antituberculosis-related organizations in a number of countries to compile photobooks that profile people who have lived with tuberculosis and healthcare professionals on the frontline treating patients.

Tuberculosis, one of the three deadliest major infectious diseases in the world together with AIDS and malaria, is the single infectious disease with the greatest number of fatalities. In 2016 a total of 10.4 million people contracted tuberculosis, and 1.7 million people died of the disease.*1 In recent years, multidrug-resistant tuberculosis (MDR-TB)*2, TB that is resistant to at least two of the most commonly used first-line anti-tuberculosis medications, is an increasing public health issue.
After a long period of research and development, DELTYBA (delamanid), a treatment for adult pulmonary MDR-TB, was approved initially in the EU, Japan, and South Korea in 2014. The drug is one of only two new anti-TB medications to be approved in almost 50 years and it has also been added to the WHO Model List of Essential Medicines.
Currently the company is advancing research and development for expansion of the indications for DELTYBA to children, and for new multidrug-resistant tuberculosis therapeutic drugs. Furthermore, considering the current situation in which new treatment options for multidrug-resistant tuberculosis are urgently needed, in 2016 the company entered into an agreement with the Stop TB Partnership’s*3 Global Drug Facility (GDF). In parallel the company has pursued drug approvals in multiple countries. Currently, through access programs deployed by government and public international institutions and expanded access by alliance partners, use of DELTYBA is being promoted in over 80 countries. In March 2017, in South Africa, Otsuka commenced a national program, the Delamanid Clinical Access Program (DCAP), to deliver delamanid quickly to patients with multidrug-resistant pulmonary tuberculosis before the granting of regulatory approval.

*1 WHO, Global Tuberculosis Report 2017
*2 When TB bacteria become resistant to at least the two most commonly used first-line medicines, isoniazid and rifampicin, the infection is called multidrug-resistant (MDR).
*3 Established in 2001 with the aim of eradicating tuberculosis. Participants include international organizations such as the WHO, government agencies, private enterprises, and patient groups. The Global Drug Facility was created as a subsidiary organization of the Stop TB Partnership to increase access to anti-TB treatments and diagnostics with assured quality in tuberculosis-endemic countries (low and medium-income countries).
 
Otsuka Pharmaceutical

Medical Food Research from a Global Perspective

Theme thumb haine

Otsuka Pharmaceutical Factory: HINE BAG, one of the concentrated liquid nutrition series for patient

Theme thumb engelead

Otsuka Pharmaceutical Factory: ENGELEAD APPLE JELLY and ENGELEAD GRAPE JELLY for people who experience difficulty swallowing

Theme thumb  o0q4440

Otsuka Pharmaceutical Factory: Taste testing Otsuka food products

Otsuka Pharmaceutical Factory, a pharmaceutical company with a strong foundation in clinical nutrition, leverages this expertise in its mission to develop original, scientifically-backed food products. These medical food products find applications in healthcare and nursing care settings. With our social responsibilities in mind, as a pharmaceutical company in a super-aging society, we have accelerated product development in Japan based on three areas: dehydration, malnutrition, and dysphagia (difficulty swallowing).
For example, OS-1, an oral rehydration solution, addresses oral rehydration therapy advocated by the WHO (World Health Organization) and is the first food for special dietary uses approved in Japan for people with mild to moderate dehydration. Other products approved as a food for special dietary use include ENGELEAD APPLE JELLY and ENGELEAD GRAPE JELLY developed specifically for those who experience difficulty swallowing, and the concentrated liquid products of HINE BAG, HINE JELLY, and HINE JELLY AQUA. The company has also developed HINE E-GEL, a digestive-type concentrated liquid nutrition with a new consistency, and PROCESS LEAD, a chew and swallow managing food. In 2017, the company launched REHADAYS, a beverage to support daily body building with the nutrition necessary for daily exercise and rehabilitation.
The company is actively working to enhance its product lineup for medical foods and bring these revolutionary products to global markets while expanding its business not only in Japan but also in other countries in Asia and elsewhere.

VOICE

写真
Going global through development of revolutionary medical foods only possible at Otsuka Pharmaceutical Factory
Tomohiro Kagawa Medical Foods Research Institute,
OS-1 Division
Otsuka Pharmaceutical Factory, Inc.
 

It is necessary for the medical foods used in the clinical nutrition field to accurately meet the needs of patients. We are aware that conducting a lot of basic and clinical research to add a high level of evidence to the products is the role of the research laboratory, and we are tackling the development of products for which applications in clinical practice can be clearly demonstrated, such as OS-1 and Hine E-Gel. We believe that Japan is not the only place where medical foods are thought to be necessary, so we are utilizing the strengths of products cultivated in Japan to launch them in the countries of Asia. For example, we have introduced semi solidified liquid meals to countries where powdered and liquid diet products are mainly consumed. Going forward we intend to conduct research that enables us to provide many products with the aim of being the world’s “best partner for clinical nutrition.”

Otsuka Pharmaceutical Factory

Support Ranging from IV Solutions to Eating Solid Food

Theme thumb foods sukiyaki

EN Otsuka Pharmaceutical: “iEat” Sukiyaki

Theme thumb %e3%82%ad%e3%83%bc%e3%83%9e%e3%82%ab%e3%83%ac%e3%83%bc

Otsuka Foods: “My Size: line! Plus” Keema Curry

Otsuka Pharmaceutical Factory develops products that comprehensively support the nutritional management of patients throughout their convalescence from the acute to the recovery phase. These range from the company’s core IV solution products and enteral nutrition products to medical foods to make patients more comfortable. In IV solutions, the company strives to develop revolutionary products that meet the needs of patients and healthcare professionals, such as the first-ever IV solution quad bag, which provides greater convenience and helps prevent mistakes in preparation.
In order to grant the wish of “eating,” for as many people as possible, of those who have difficulty in eating regular food and are dependent on purees and finely chopped foods, EN Otsuka Pharmaceutical has developed iEat series of eating recovery assisting products which provide nutritious foods that retain the look and taste of the food patients are used to eating, yet are soft enough to be broken down in the mouth with just the tongue. The iEat series have been provided to the home-based care households, senior care houses, and hospitals. The company also conducts lecture activities to provide health information for the elderly, and the explanation and food tasting of iEat. At the same time, the company has been involved in the production, distribution, and development of a product line which supports oral ingestion. The product line includes REFRECARE series of oral care products, and RACOL-NF SemiSolid for enteral use, which contributes to securing the time for rehabilitation enabling short period of gastrostomy administration.
In 2010, Otsuka Foods launched its My Size series of retort food products so that the consumers can easily visualize the size of the meal. The retort products, including curry ingredients, rice bowl toppings, and packaged rice, prepared in an easy-to-see 100 or 150 calories per serving also ensure deliciousness, thus have gained considerable support. In 2016, the company launched its My Size: Iine! Plus series of products sold exclusively in Japanese pharmacies. The series is designed for people concerned not only about calories, but also about intake of salt, proteins, and sugars. As opportunities for health management and nutrition guidance campaigns increase at regular prescription drug pharmacies in Japan, and the Japanese government moves to create a system of Health Support Pharmacies, the My Size: Iine! Plus series is gaining the attention of consumers looking for products to support a healthy diet.
Otsuka Pharmaceutical Factory, EN Otsuka Pharmaceutical, Otsuka Foods
Health
Addressing Unmet Needs
Response thumb otsuka pic11 1

Addressing Unmet Medical Needs

Otsuka group medical-related businesses develop revolutionary new medicatio...

Health
Addressing Unmet Needs
Response thumb  img 7755 %e5%b7%ae%e3%81%97%e6%9b%bf%e3%81%88170707

Addressing Yet-to-be-imagined Consumer Needs

In our nutraceutical business, Otsuka Pharmaceutical leverages our medical-...

Health
Addressing Unmet Needs
Response thumb img fightback

Global Initiatives for Public Health

Tuberculosis, one of the three deadliest major infectious diseases in the w...

Health
Addressing Unmet Needs
Response thumb haine

Medical Food Research from a Global Perspective

Otsuka Pharmaceutical Factory, a pharmaceutical company with a strong found...

Health
Addressing Unmet Needs
Response thumb foods sukiyaki

Support Ranging from IV Solutions to Eating Solid Food

Otsuka Pharmaceutical Factory develops products that comprehensively suppor...

Health
Raising Awareness of Health
Response thumb %e5%a4%a7%e5%a1%9a%e8%a3%bd%e8%96%ac %e7%86%b1%e4%b8%ad%e7%97%87%e4%ba%88%e9%98%b2%e5%95%93%e7%99%ba%e6%b4%bb%e5%8b%95

Building Awareness of Prevention of Heat Disorders

Ever since the launch of POCARI SWEAT, Otsuka Pharmaceutical has been carry...

Health
Raising Awareness of Health
Response thumb img womanhelth01

Raising Awareness of Women’s Health

The average lifespan in Japan, which is over 80 years old for both men and ...

Health
Raising Awareness of Health
Response thumb %e3%83%92%e3%82%9a%e3%83%b3%e3%82%af%e3%83%aa%e3%83%9b%e3%82%99%e3%83%b3%e6%b4%bb%e5%8b%95%e3%82%92%e5%bf%9c%e6%8f%b4

Supporting the Pink Ribbon Campaign

The Pink Ribbon campaign is a worldwide effort to raise awareness on, distr...

Health
Raising Awareness of Health
Response thumb %e5%a4%a7%e9%b5%ac%e8%96%ac%e5%93%81 survivorship.jp

Health Information Online

The Otsuka group is involved in awareness-building activities to promote pr...

Health
Raising Awareness of Health
Response thumb %e5%a4%a7%e5%a1%9a%e9%a3%9f%e5%93%81

My First Water Project

Otsuka Foods has been running the My First Water Project, which aims to dis...

Health
Raising Awareness of Health
Response thumb %e5%86%8a%e5%ad%90%ef%be%97%ef%bd%b2%ef%be%9d%ef%be%85%ef%bd%af%ef%be%8c%ef%be%9f

Otsuka Health Comic Library

Otsuka Holdings published the Otsuka Health Comic Library Volume 4 “Do you ...

Health
Raising Awareness of Health
Response thumb %e7%b5%b1%e5%90%88%e5%a4%b1%e8%aa%bf%e7%97%87%e3%83%95%e3%82%a9%e3%83%bc%e3%83%a9%e3%83%a0img 1136

Raising Awareness about Illness

Since 2009, Otsuka Pharmaceutical has provided support for forums on schizo...

Health
Raising Awareness of Health
Response thumb img twenty

Producing Informative Materials for Cancer Patients

Taiho Pharmaceutical is developing and providing various materials that can...

Health
Raising Awareness of Health
Response thumb oathas%e3%83%ad%e3%82%b3%e3%82%99

Activities for medical professionals

As Japan’s society continues to age and in light of the need for pharmacies...